List of Tissue Engineering Companies in Sweden - 2

Search through the full list with powerful filtering options

Company	About
AKIRA Science stockholm, stockholm county, sweden	We, at Akira Science - a Stockholm based tech start-up-, use the latest manufacturing technologies to provide you with pliable scaffolds for soft tissue engineering. Our solutions results from the synergistic combination of degradable polymers synthesis expertise, mechanical simulation approach to develop suitable scaffold design to tailor the biological response.
Fluicell Flöjelbergsgatan 8c, Mölndal, Vastra Gotaland County 431 37, SE	Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell's first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.

Company

About

AKIRA Science

stockholm, stockholm county, sweden

We, at Akira Science - a Stockholm based tech start-up-, use the latest manufacturing technologies to provide you with pliable scaffolds for soft tissue engineering. Our solutions results from the synergistic combination of degradable polymers synthesis expertise, mechanical simulation approach to develop suitable scaffold design to tailor the biological response.

Fluicell

Flöjelbergsgatan 8c, Mölndal, Vastra Gotaland County 431 37, SE

Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell's first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.